NASDAQ · KRYS
Healthcare · Biotechnology
$300.88
Up+$0.63 (+0.21%)
Updated Nov 7, 2026, 5:11 AM
SID Score
5.3/10
Composite research score
Smart Money
58/100
Neutral
Price performance · KRYS
1M range · 0 trading sessions · Daily adjusted prices
KRYS does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning KRYS.
Company
Market Activity
Research & News
KRYS research
Company profile and research snapshot.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 3, 2026 | RBC Capital | Outperform | — |
| Nov 3, 2026 | TD Cowen | Buy | — |
| Nov 3, 2026 | Citigroup | Buy | — |
| Oct 15, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 24, 2026 | Goldman Sachs | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 27, 2026
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · Oct 26, 2026
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Benzinga · Oct 22, 2026
Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 31.65% on an annualized basis producing an average annual return of 42.52%. Currently, Krystal Biotech has a market capitalization of
Yahoo · Oct 22, 2026
PITTSBURGH, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its third quarter 2026 financial results on Monday, November 2, 2026, prior to the open of U.S. markets. The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, November 2, 2026, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: https://www.webcas
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KRYS.
